Full Archive
It could take time for mesothelioma patients to have better lung function after pleural mesothelioma surgery since some patients have better lung function a year after surgery compared to the days and weeks after the operation. Researchers in Japan published their findings in Integrative Cancer Therapies. There were 24 male patients with pleural mesothelioma tested…
Primary Outcome Measures Response rate [ Time Frame: Up to 4 years after study activation ] Will be compared between arms. Secondary Outcome Measures Major pathologic response rate [ Time Frame: Up to 3 years ] The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square test will be used to…
Two immunotherapy drugs, tremelimumab and durvalumab, are showing to be a successful second line treatment for pleural mesothelioma when combined. This could mean that more treatments will be approved for the treatment of mesothelioma. The results of this phase II clinical trial were published in the Lancet Respiratory Medicine from the Department of Oncology at…
Primary Outcome Measures To evaluate the efficacy of atezolizumab in patients with MPM in terms of DFS [ Time Frame: 12 weeks ] DFS, defined as the time from initiation of study treatment to first recurrence of disease or death for any cause, whichever occurs first. Secondary Outcome Measures To evaluate the safety of atezolizumab in patients with MPM…
There are some good results coming from a German study looking at Pleurectomy and Decortication surgery (P/D) being combined with HITHOC. Pleurectomy surgery is surgery that removes mesothelioma tumors but leaves the lung intact while HITHOC is a method of adding heated chemotherapy to the pleural area, sparing the rest of the body. When used…
Primary Outcome Measures To evaluate the efficacy of the treatment [ Time Frame: From the date of randomization to the date of last follow up, assessed up to 24 months ] To determine the efficacy of M7824 in terms of the Progression Free Survival (PFS) assessed by the investigator according to the modified Response Evaluation Criteria in Solid Tumors…
A study at the Duke University Medical Center has found that radiation does not extend survival in pleural mesothelioma patients. A dual registry analysis was performed to determine the effectiveness of aggressive surgery and radiation. Adjuvant radiation is recommended as a treatment by many cancer centers including the U.S. National Comprehensive Cancer Network and the…
Pleural mesothelioma could soon have a new approved treatment option. The Food and Drug Administration just granted orphan drug status to ONCOFID-P for the treatment of the cancer. It is currently being studied for invasive bladder cancer, but data from lab and mice models is showing it could be beneficial for pleural mesothelioma as well.…
Tumor Treating Fields were approved for treating mesothelioma, and while they are effective, researchers want to make them more effective for the cancer. A researcher at the Humanitas University in Milan is studying different drug combinations to use with Tumor Treating Fields. The goal is to find a drug that has a synergistic effect with…
Researchers at the Memorial Sloan Kettering Cancer Center are experimenting with a combination of CAR-T cell therapy and Keytruda, a PD-1 blocker for the treatment of pleural mesothelioma. This is the first time that these two therapies have been combined. The results were recently published in Cancer Discovery. Mesothelioma is an aggressive cancer of the…
